Background {#Sec1}
==========

Stroke is one of the leading causes of death and disability worldwide \[[@CR1]\], with 10.3 million of new strokes and 113 million of disability-adjusted life years per year \[[@CR2]\]. Stroke victims face an uncertain future and a life severely affected by disability. The most common type of stroke is the ischemic stroke (IS), accounting for 87% of all strokes. It is characterized by the occlusion within an arterial vessel supplying blood to an area of the brain, resulting in a corresponding loss of neurological function. It mainly occurs in elderly patients of both sexes with often multiple comorbidities (diabetes mellitus, hypertension, hyperlipidemia, obesity) \[[@CR3]\]. Currently, the only treatments available in the acute phase that have demonstrated safety and effectiveness are intravenous fibrinolytic treatment \[[@CR4], [@CR5]\] and mechanical thrombectomy \[[@CR6]\]. Unfortunately, even today many patients cannot benefit from these treatments due to contraindications, time of evolution of the symptoms or restricted access to mechanical therapies that are currently only offered in highly sophisticated hospitals. Thus, there is a need for better and wider therapies to boost patient adherence.

The effectiveness of neuroprotective therapies has a great potential to not only increase the benefits of available reperfusion therapies but also to provide an advisable medical procedure for patients who are not eligible for current treatments. However, translation of most neuroprotective trials from the bench to the emergency room has failed so far, they did not demonstrate efficacy on IS patients, even with promising results in a few preclinical studies \[[@CR7]\]. One of the main explanations for this failure is that the majority of neuroprotective drugs studied only act on a level of the complex cascade of phenomena that occur in ischemia/reperfusion \[[@CR7]--[@CR9]\]. The feasibility of neuroprotection in IS is still an unresolved inquiry. To date, all trials of neuroprotectant compounds have failed to provide basis and build better trials.

Remote ischemic perconditioning (RIPerC) represents a new paradigm in neuroprotective therapies \[[@CR10], [@CR11]\] and it has the potential ability to protect the ischemic brain from injury until reperfusion and, later to protect the brain from reperfusion injury. RIPerC consists of short and controlled cycles of ischemia-reperfusion applied to one limb during the establishment of cerebral ischemia \[[@CR11]\]. Until now, the underlying mechanisms of remote ischemic conditioning (RIC) include neurovascular protection, induced anti-inflammatory action and neuronal protection against excitotoxicity; paired together with mitochondrial protection, circulating inflammasome activation and/or transcriptional regulation of neuroprotective pathway \[[@CR12]\] (Fig. [1](#Fig1){ref-type="fig"}). However, there is limited data about the clinical translation of RIPerC in IS patients. Fig. 1Schematic diagram of the potential and expected neuroprotective effects of remote ischemic perconditioning (RIPerC) on ischemic stroke at the acute phase. RIPerC refers to the application of several cycles of press and release by an automatic device in a prehospital setting (ambulance) to an upper non-affected limb. Its clinical application is safe, feasible and well tolerated. The underlying RIPerC mechanisms include mitochondrial protection, activation of inflammasome, neurovascular protection and specific anti-inflammatory pathway regulation. Ongoing clinical trials will provide new information on the best RIPerC intervention strategy and reveal underlying neuroprotective mechanisms. Abbreviations: CBF, cerebral blood flow; TNF-a, tumor necrosis factor alpha; IL-6, interleukin 6; IL-10, interleukin 10; SDF-1a, stromal cell-derived factor-1; HIF-1a, hypoxia-inducible factor 1-alpha; mTOR, mammalian target of rapamycin; MMPs, matrix metallopeptidases; ROS, reactive oxygen species

Endogenous cerebral neuroprotection of RIPerC on IS patients is a new paradigm that aims to enhance the brain resilience to ischemia and it has the potential to improve the clinical outcome of affected individuals. For that, a systematic review of the published articles and clinical trials on RIPerC applied to IS patients was performed to evaluate and summarize the findings.

Search strategy and selection criteria {#Sec2}
--------------------------------------

A systematic review of prospective cohort studies was conducted (prehospital-based and hospital-based cohorts) on acute IS patients under RIPerC and placebo-arms. Studies published from January 2000 to March 2020 were included. PRISMA recommendations were followed \[[@CR13]\].

Identification, screening and eligibility for included studies was performed by two reviewers (F.P., G.A.). Bias analysis was unable to be performed because of the ongoing clinical trials. The search was conducted using the electronic databases: Pubmed and ClinicalTrials.gov. Search limits were English language, human and 2000-current. The search terms were: 'remote ischemic conditioning' AND 'acute ischemic stroke' OR 'remote ischemic perconditioning' AND 'acute ischemic stroke' OR 'remote ischemic postconditioning' AND 'acute ischemic stroke'. Prospective human cohort studies that applied RIPerC in IS patients were included. Studies accepting inclusion beyond 48 h from the onset of symptoms were excluded. The last database search was conducted on September 2019. Following screening of abstracts, full-text copies of potentially eligible papers were retrieved and assessed for eligibility.

Results {#Sec3}
=======

Electronic database search yielded 32 publications and 27 clinical trials of which 19 studies were finally included in the systematic literature review (Fig. [2](#Fig2){ref-type="fig"}). Among the 31 publications identified on Pubmed search, nine articles were not related to stroke (29%), four articles applied chronic PostRIC (13%), three articles were reviews of literature, three articles described design of the studies or protocols \[[@CR14]--[@CR16]\], two articles were on subarachnoid hemorrhage patients, one article was a sub-study and four articles were not eligible. After applying the inclusion criteria (acute ischemic stroke-AIS patients and application of remote ischemic perconditioning-RIPerC) and the studies that accept inclusion beyond 48 h from the onset of symptoms were exclude; a total of 6 articles were included and analyzed in the systematic review \[[@CR16]--[@CR21]\], note that 4 out of the 6 papers were previously registered as clinical trials \[[@CR18]--[@CR21]\]. Twenty-seven randomized clinical trials (RCTs) were identified on clinicaltrials.gov. Of these RCTs, 6 (22.2%) applied PostRIC and 4 (14.8%%) were not considered after inclusion/exclusion criteria were applied. Seventeen RCTs were further considered in the present systematic review (NCT0097596 \[[@CR21]\], RESCUE-BRAIN \[[@CR15], [@CR22]\], REVISE-1 \[[@CR18]\], rtPA-RIC1 \[[@CR19]\], ReCAST-2, rtPA-RIC, REMOTE-CAT, TRIPCAIS, REVISE-2, RICE PAC, SERIC-AIS, RICAMIS, RESIST \[[@CR14]\], ICARUS, SERICT-AIS, RIC-SIID, PROTECT I). Table [1](#Tab1){ref-type="table"} provides a summary of study design characteristics of the 19 RTCs on RIPerC application on IS patients. Fig. 2PRISMA diagram details the search and selection process of RIPerC systematic review of literatureTable 1Summary of characteristics of 19 clinical trials and research papers included in this systematic review on remote ischemic per-conditioning application on acute ischemic stroke patientsNTC Number\
Acronym/RefCountryRegistered yearEstimated enrollmentAgeCriteriaTime before inclusionPrehospital interventionApplication\
\# cycles\
PressureApplication of RICInterventionPrimary outcome measuresRecruitment statusNCT0097596 \[[@CR21]\]Denmark2009120\> 18Ischemic stroke and rtPA therapy candidate, cerebral infarct showed on MRI4.5 hYesManual rIPerC,4 × 5′Up to 25 mmHg above systolic BPNon-affected upper extremityOne timeControl group: not RIC simulationDifference in infarct growth (PWI-DWI) after 24 h (Salvage index)Completed and publishedNCT02189928RESCUE-BRAIN \[[@CR15], [@CR20]\]France2014200\> 18Carotid ischemic stroke, confirmed by MRI, NIHSS ≥5 and ≤ 25\< 6 hNoDevice,4 × 5′110 mmHgNon-affected lower extremityOne time after initial MRIControl group: RIC simulation (no pressure)Infarct volume by MRI at 24 hmRS at 90 daysCompleted and publishedRECAST \[[@CR17]\]UK2015^a^26\> 18Ischemic stroke with motor deficits on arm and/or leg\< 24 hNoManual RIC,4 × 5′Up to 20 mmHg above systolic BPNon-affected upper extremityOne timeControl group: manual RIC simulation (30 mmHg)Tolerability and feasibilityComplete and publishedNCT03210051REVISE-1 \[[@CR18]\]China20172018--80Ischemic Stroke and endovascular recanalization\< 6 hNoDevice,5 × 5′200 mmHgBoth upper extremitiesOne timeNo control groupFrequency of adverse events at 90 daysCompletedNCT03231384rtPA-RIC1 \[[@CR19]\]China201730\>  18Confirmed Ischemic Stroke and rtPA therapy on going\< 4.5 hNoDoctormate device,5 × 5′200 mmHgBoth upper extremitiesOne time 2 h after rtPA therapy; twice daily for 6 days.Control group: not RIC simulationFeasibility of RIC within 7 daysCompletedNCT02779712ReCAST-2UK2016120\> 18Ischemic stroke6 hNoManual,4 × 5′Up to 20 mmHg above systolic BPNon-affected upper extremityGroup1: one time. Group2: two times (repetition after 60 min). Group3: twice daily for 4 days.Control group: manual RIC simulation (30 mmHg)Trial feasibility at 90 daysCompletedNCT02886390rtPA-RICChina20166018--80Clinical sign and symptoms of acute ischemic stroke and rtPA therapy candidate,NIHSS score ≥ 4 and ≤ 154.5 hNoDoctormate device,5 × 5′200 mmHgBoth upper extremitiesOne time within 2 h after rtPA therapyControl group: not RIC simulationInfarct volume Infarct volume by MRI at 72 hRecruitingNCT03375762REMOTE-CATSpain2017572\> 18Clinical signs and symptoms of acute ischemic stroke, RACE \> 0,RACE motor \> 0,known-onset stroke\< 8 hYesDevice,5 × 5′,200 mmHgNon-affected upper extremityOne time in the ambulanceControl group: RIC simulation (no pressure)Infarct volume by MRI at 72 hmRS at 90 daysRecruitingNCT03218293TRIPCAISChina2017120allConfirmed ischemic stroke by neuroimaging, accordance with GTAIS and accomplish rtPA therapy\< 4.5 hNoRIPC Device,5 × 5'Non-affected upper extremityOne time after rtPA therapyControl group: not RIC simulationVEGF and bFGF levels at 14 and 90 daysRecruitingNCT03045055REVISE-2China201718018--80Confirmed Ischemic Stroke,NIHSS ≥6,Endovascular recanalization\< 6 hNoDevice,4 × 5′200 mmHgUpper extremityOne timeControl group: RIC simulation (60 mmHg)Infarct volume at 3--7 days post-strokeNot recruiting yetNCT03152799RICE PACUK201760\>  18Ischemic Stroke, proximal anterior occlusion,endovascular recanalization\< 6 hNoManualNon-affected upper/lower extremityOne timeControl group: RIC simulationInfarct volume by MRI at 90 daysNot recruiting yetREPOST \[[@CR16]\]Netherlands2017^b^200\> 18Ischemic stroke\< 12 hNoManual4 × 5′Up to 20 mmHg above systolic BPUpper extremityTwice daily ×  4 daysControl group: twice daily ×  7 days (50 mmHg)Infarct volume by MRI at 4 daysRecruitingNCT03669653SERIC-AISChina201891218--80Confirmed Ischemic Stroke,NIHSS score \> 5 and ≤ 25\< 12 hNoDevice,4 × 5′200 mmHgBoth upper extremitiesTwice daily ×  7 daysControl group: twice daily ×  7 days (60 mmHg)mRS at 90 daysRecruitingNCT03740971RICAMISChina20181800\>  18Confirmed Ischemic Stroke by neuroimaging, NIHSS score ≥ 6 and ≤ 1648 hNo----Twice one dayControl group: not RIC simulationNeurological score at 90 daysRecruitingNCT03481777RESIST \[[@CR14]\]Denmark20181500\> 18Clinical signs and symptoms of stroke, PreSS ≥1\< 4 hYesDevice,5 × 5',200 mmHgNon-affected upper extremityTwo times, one at the ambulance and one 6 h after in the hospital. Some patients get twice daily for 7 days.Control group: RIC simulation (20 mmHg)mRS at 90 daysRecruitingNCT03481205ICARUSUS20181018--85Ischemic stroke, air transportation to a Stroke unit for endovascular recanalization,NIHSS ≥6--NoDoctormate Device,3--5 × 5′200 mmHgBoth upper extremitiesOne time in route (airplane) to Stroke centerNo control groupFeasibility of delivering RLIC by air medical crewsNot recruiting yetNCT04027621SERICT-AISChina20195018--80Confirmed Ischemic Stroke and rtPA therapy,NIHSS score \> 5 and ≤ 25--NoDevice,4 × 5′200 mmHgNon-affected upper extremityTwice within 6--24 h from rtPA therapy,Control group: twice within 6--24 h from rtPA therapy (60 mmHg)Frequency of adverse events at 7 days or earlierNot recruiting yetNCT04069546RIC-SIIDChina201930\>  18Confirmed Ischemic Stroke,NIHSS ≤15\< 48 hNoDevice,5 × 5′180 mmHgUpper extremityOne time \< 48 h from stroke symptom onsetControl group: not RIC simulationPlasma levels of mHLA-DR at 2 and 7 days, pneumonia incidence within 7 daysNot recruiting yetNCT03915782PROTECT IFrance2019126\>  18Ischemic Stroke, full occlusion of the MCA (occlusion of M1 and/or proximal M2), confirmed by MRA and DWIEndovascular recanalization\< 6 hNoDevice,4 × 5′200 mmHgUpper extremityOne time after first MRIControl group: RIC simulation (30 mmHg)Infarct volume by MRI after 24 h from endovascular recanalizationNot recruiting yet*Abbreviations*: *bFGF* Basic fibroblast growth factor, *DWI* Diffusion weighted imaging, *GTAIS* Guideline of thrombolysis in Acute Ischemic Stroke, *MCA* Middle cerebral artery, *MRI* Magnetic resonance imaging, *mRS* Modified Rankin Scale (mRS) Score, *NIHSS* National institute of Health Stroke Scale, *PreSS* Prehospital Stroke score, *PWI-DWI* Perfusion-weighted imaging-diffusion-weighted imaging, *RACE* Rapid arterial occlusion evaluation scale, *RIC* Remote ischaemic conditioning, *RLIC* Remote limb ischemic conditioning, *rt-PA* Recombinant tissue plasminogen activator, *VEGF* Vascular endothelial growth factor^a^Registered in ISRCTN^b^Registered in Netherlands Trial Register

The first research paper was published by Hougard et al. in 2014 \[[@CR21]\]. Of 443 randomized patients, 247 received manual remote ischemic conditioning (mRIC) during transportation in the ambulance to the hospital. After adjustment for baseline multimodal magnetic resonance imaging (MRI) findings, voxel-wise logistical analysis showed better radiological evolution of mRIC treated patients than non-treated patients. However, there were no significant differences in clinical neurological outcome between mRIC and control groups. The paper of Che et al. \[[@CR19]\], included only 30 patients treated with recombinant tissue plasminogen activator (rt-PA). Zhao et al. \[[@CR18]\] demonstrated that RIC is safe in 20 patients who underwent mechanical thrombectomy. Moreover, England et al. \[[@CR17]\] confirmed the applicability and feasibility of RIC on 13 IS patients within 24 h after the onset of symptoms. Furthermore, RIC was associated with changes of plasma biomarkers related to ischemic tolerance (IT) phenomena, such as HSP27 and phosphorylated HSP27, whose expression was significantly different when both arms (control vs. experimental) of the trial were compared (*n* = 13) \[[@CR17]\]. These four publications included a limited and small number of recruited subjects \[[@CR17]--[@CR19], [@CR21]\]. In contrast with previous studies, the multicenter RESCUE-BRAIN trial \[[@CR20]\] was not only focused on IS patients who received or were candidate for revascularization therapies. It included 188 patients with confirmed carotid IS who underwent magnetic resonance imaging within 6 h after the onset of symptoms, and 171 (91%) patients received a recanalization therapy. In RESCUE_BRAIN trial, RIPerC was applied using an electronic device on the unaffected lower extremity (4 cycles of 5-min inflations and 5-min deflations). Brain infarction volume growth, which was the main outcome, was not significantly different between the intervention and control groups. In addition, no significant differences at 90-days mRS and mortality were observed between the two groups.

Up to now, there are 19 RCTs identified (where?) and 17 (89.5%) of them were registered in clinicaltrials.gov. Among them, 14 (73.4%) have been registered in the last 3 years, 9 (47.4%) have been developed in China, 9 (47.4%) in Europe and one (5.3%) in United States. Relating to the estimated number of enrolled patients on selected RTCs, special attention must be paid on RICAMIS (*n* = 1800), RESIST (*n* = 1500, 14), SERIC-AIS (*n* = 912) and REMOTE-CAT (*n* = 572).

There is a high variability in the inclusion and exclusion criteria among trials. Five RCTs require radiological confirmation of acute cerebral infarction despite of the subsequent treatment received (SERIC-AIS, RIC-SHD, RICAMIS, RECAST, RESCUE BRAIN). Finally, Danish RESIST RCTs, Spanish REMOTE-CAT and British RECAST-2 include patients that met stroke code criteria. Both REMOTE-CAT and RESIST consider the score of prehospital scales: RACE scale \[[@CR23]\] and Prehospital Stroke Score (PreSS), respectively. Only 6 trials (31.6%) set up an upper age limit as an inclusion criterion. Like in previous RCTs of Hougard et al. \[[@CR21]\] and Che et al. \[[@CR19]\], three on-going RCTs (SERICT-AIS, rtPA-RIC, TRIPCAIS) are focused on the RIC's role as an adjuvant treatment of thrombolytic therapy. In contrast, REVISE-2, PROTECT I and REVISE-1 \[[@CR18]\] included patients who underwent thrombectomy.

Heterogeneity is also evidenced by the number of RIC cycles applied: 7 (36.8%) RCTs use 5 cycles, one (5.3%) RCT uses between 3 and 5 cycles, and the rest of the trials use 4 cycles. Thirteen (68.4%) RCTs perform a single application of RIC. Conversely, SERIC-AIS and RESIST \[[@CR14]\] have planned up to two applications throughout 7 days, like in the finished study of Che et al. \[[@CR19]\]; only REPOST has planned to applied during 4 days \[[@CR16]\]. The application of RIC is located in the non-paretic lower limb only in one RCT \[[@CR15]\], on both upper extremities in five (26.3%) RCTs, and on upper or lower non-paretic extremities in one (5.3%) RCT. In most cases, the application is restricted to the unaffected upper limb. The application of the RIC is manual in 5 (26.3%) RCTs: two completed RCT \[[@CR17], [@CR21]\], REPOST \[[@CR16]\], RECAST 2 and RICE PAC. A simulated control group is only included in little over half of the considered RCTs.

Certain variability of timing of RIC application is observed within all selected studies. Concretely, in the RESIST trial, temporal inclusion criterion is set at \< 4 h while in RIC-SIID and RICAMIS is extended to 48 h. RCTs focused on patients treated with intravenous fibrinolysis set the maximum time for the evolution of symptoms to 4.5 h. Instead, among RCTs assessing the effect of RIC on thrombectomy, the time is set up at 6 h. The Spanish REMOTE-CAT trial includes patients with less than 8 h of evolution of symptoms.

Only three RCTs, REMOTE-CAT, RESIST and the previous published by Hougard et al. \[[@CR21]\], initiate the application of RIC in a prehospital setting, usually in the ambulance transportation of the patient to the hospital or stroke care center. Despite the low sample size (*n* = 15), ICARUS trial aims to reveal the feasibility of RIC application on thrombectomy candidates who are transported to comprehensive stroke centers by aircraft.

C, outcome measurements, was there any information on the size of the final infarct volume, perfusion, recurrent stroke?

The high heterogeneity within RCTs is also observed on the main endpoints (Fig. [3](#Fig3){ref-type="fig"}) and outcome measurements. The RCTs yielding the highest number of enrolled patients are still on-going (REMOTE-CAT, SERIC AIS, RESIT and RICAMIS) and all have considered the clinical endpoint as the main endpoint. In medium size studies and endovascular therapy related studies, the main endpoints are infarct volume and/or neuroimaging outputs. On the first research published paper on the application of RIC on IS patients, the main endpoint considered was the neuroimaging outcome \[[@CR21]\]. Ischemic tolerance-related biomarkers are included in TRIPCAIS and RIC-SIID trials. However, other RCTs would also study biomarkers to detect differential expression changes. Small-size recruited patients studies demonstrate whether RIC application is feasible in AIS patients and AIS patients treated with rt-PA and/or endovascular therapy \[[@CR17]--[@CR19]\] (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plot of included clinical trials and research papers summarized by ischemic stroke (grey dots), rt-PA therapy (black dots) and endovascular treatment (white dots). Dots height is proportional to estimated enrollment. The analysis included data from 18 studies on four variables: clinical endpoints, neuroimaging endpoint, biomarker discovery and feasibility

Discussion {#Sec4}
==========

The current systematic review of RIPerC in IS patients has revealed a noticeable number of trials registered in clinicaltrials.gov, especially in the last 3 years. Globally, a broad heterogeneity is observed among RCTs regarding the number of recruited patients, inclusion criteria, number of RIPerC applied cycles, location of the application, and the main endpoints. Despite the high heterogeneity of current studies, they would all contribute to improve RIPerC effects and mechanisms of action. The first published evidence of RIPerC in IS patients was limited to patients that underwent intravenous alteplase therapy \[[@CR21]\]. Moreover, according to new advances in stroke, five new studies have been focused on patients treated with endovascular therapy. However, preclinical data have demonstrated that RIC during acute ischemia is effective when applied both alone and in combination with revascularization therapies \[[@CR24]\]. For that, results of the largest RCTs (REMOTE-CAT, SERIC AIS, RESIST \[[@CR14]\] and RICAMIS), which all include IS patients despite of the acute applied treatment, would be of enormous interest.

Only one RCT applied RIC manually \[[@CR21]\], but one out of three patients fully complete the cycles. Using an automated RIC device allows that RIC can be continued once the patient arrives to the stroke care unit and the full dose can be administered. For that, most of the RTCs are currently using automatic devices to apply RIPerC. Concretely, 14 out of 17 new trials use automatic devices. Another important issue is the number of cycles and the place of application. Most RIC trials in Cardiology \[[@CR25], [@CR26]\] and the first trials in IS used the four-cycle protocol, probably due to literature tradition and preclinical studies. Preconditioning was first demonstrated in a dog model of myocardial ischemia using a four-cycle protocol \[[@CR27]\]. Afterwards, both RIC before ischemia \[[@CR28]\] and RIC during ischemia were first documented using the same protocol \[[@CR29]\]. The neutral clinical results of Hougaard et al. \[[@CR21]\] and Pico et al. \[[@CR20]\] trials arise the need to increase the RIC stimulus and repetitions. Recent studies in preclinical models also addressed it to optimize the efficacy and optimal duration of RIPerC \[[@CR30]\]. In a rat model of cerebral ischemia, repeated remote post-conditioning during 14 days after reperfusion significantly decrease the volume of infarction \[[@CR31]\]. There are some promising experiences in chronic postconditioning among intracranial stenosis patients \[[@CR32]\] and patients with cerebral small-vessel disease \[[@CR33]\] using five-cycle protocol. Currently, on-going REMOTE-CAT and RESIST trials use a five-cycle RIC protocol. Moreover, combination of RIPerC and postconditioning during 4 to 7 days is assessed in the RESIST trial \[[@CR14]\], ReCAST-2 \[[@CR17]\], REPOST \[[@CR16]\] and SERIC-AIS trial. Although, the volume of muscle mass affects the efficacy of the RIC intervention \[[@CR34]\], only one study proposed RIC application in a leg \[[@CR20]\]. It has been described that one in four IS patients has silent peripheral arterial disease \[[@CR35]\], for that it has suggested that the upper arm would be the best location because of safety reasons. One and two-limb conditioning were equally protective according to preclinical models \[[@CR30]\]. At present, how the neuroprotective stimulus is transferred or its mechanisms of actions in the brain are not fully understood \[[@CR36]\], but it is known that the translation of the RIC sensory signal to the brain is crucial \[[@CR37]\] and RIC should be applied in the non-affected arm.

A prehospital administration of RIC in the ambulance transportation was first proposed by Hougard et al. \[[@CR21]\] and it is established in REMOTE-CAT and RESIST \[[@CR14]\] trials. RIC effects are time-dependent, so early initiation of RIC is fundamental \[[@CR38]\].

Pre-hospital screening scales should be used during transportation and RIPerC application to correctly randomize and recruit IS patients. When the Face Arm Speech Test was used, an increased proportion of patients with transient symptoms in the intervention group was observed \[[@CR21]\]. It was not clear whether it was a RIC's effect or there was a bias in the selection. At present, both REMOTE-CAT and RESIST \[[@CR14]\] trials have a pre-hospital screening performed by RACE and PreSS scores, respectively. Patients should be properly balanced using prehospital stroke scores.

Recently, it has been reported that RIC improves the clinical evolution of myocardial infarction and it reduces the final lesion size \[[@CR25], [@CR39]\]; but a recent large RCT, with more than 5000 patients, reported no effects on clinical outcomes \[[@CR40]\]. Cerebral and heart ischemia might differ on its own characteristics \[[@CR41]\], because IS has a variety of pathogenic mechanisms not present in heart ischemia. The rupture or erosion of vulnerable plaques in coronary arteries are the most common cause of heart ischemia \[[@CR42]\], while the embolism from arterial or heart sources is the main cause of IS \[[@CR43]\]. Altogether, we would anticipate that underlying RIC mechanisms and clinical outcomes in IS patients will be different and the expected results of the currents RCTs are promising.

Implications for future research {#Sec5}
--------------------------------

Currently, there are some on-going randomized clinical trials that will provide valuable information on RIPerC in ischemic stroke patients. However, future studies should carefully examine patient recruitment, RIPerC application settings, proper outcome measurements and neuroimaging follow-up protocols. All optimization and efforts will improve the current knowledge and address new medical strategies and management of stroke patients.

According to the RESCUE BRAIN study \[[@CR20]\], the application of RIC during/after partial or complete reperfusion was futile, and it did not reduce the consequences of reperfusion injury. So, this might suggest that RIC should be applied differently. In this line, preclinical data and results from pilot studies showed that RIC should be applied as soon as possible, preferable during patient transportation (prehospital setting, ambulance) to a Hospital, in order to avoid the penumbral tissue recruitment and extend the time window for further application of reperfusion therapies. In this context, an early triage and stratification of the patients using prehospital scales are essential, and it will also help in the randomization process of the clinical trials (REMOTE-CAT, NCT03375762; RESIST \[[@CR14]\]). The accuracy of prehospital scales is fundamental to identify or confirm a possible early prehospital treatment effect, like it was suspected in previous studies \[[@CR21]\]. For that, the initial use of prehospital scales is a strong recommendation along RIPerC application in a prehospital setting and/or as soon as stroke symptoms are detected.

Automatic devices should be used to ensure completion of cycles and to document the treatment compliance. Another reason for the futile results of RESCUE BRAIN \[[@CR20]\] study and the study of Hougaard et al. \[[@CR21]\] would be that the 4 × 5 cycles of RIPerC stimulus was not sufficient. To overcome this issue, increasing up to five cycles and/or the stimulus repetition twice daily for the first 5 to 7 days would be an improvement. In the other hand, better selection of included patients in clinical trials can boost patient stratification.

Collateral status correlates with stroke severity and reperfusion outcomes, due to their ability to restrict the growth of penumbral territory \[[@CR44]\]. Although the underlying mechanisms of RIC are still not fully known, some recent preclinical studies have showed an enhancement of collateral circulation \[[@CR45], [@CR46]\]. For that, the role of collaterals is essential in large vessel occlusion (LVO) patients, whom are also candidates to undergo mechanical thrombectomy \[[@CR47], [@CR48]\] in admitted hospital, or they are candidates to be transferred to a Comprehensive Stroke center. Altogether, LVO patients would be a group of special interest to study the RIC effects.

Recent published data have highlighted that RIC is safe and feasible \[[@CR17]--[@CR21], [@CR49]\] similarly to RCTs involving patients with myocardial infarction \[[@CR25]\]. For that, the main outcomes of the ongoing and future RCTs on RIPerC have a strong clinical interest. According to stroke treatment academic industry roundtable (STAIR) recommendations \[[@CR50]\], 24-h NIHSS, 7-days mRS and 90-days mRS should be considered to be the standard clinical endpoints in acute stroke trials. Follow-up infarct volume on brain imaging is also informative, based on preclinical data that reported an effect of RIC on final brain infarction volume when it was used alone or in combination with alteplase \[[@CR24]\]. This is recommended by both STAIR \[[@CR50]\] and The Stroke Imaging Research (STIR) group \[[@CR47]\]. More concretely, STIR estimated that sample sizes based on lesion volumes should be about one fourth of those based on mRS \[[@CR51]\], so the imaging endpoint has the advantage of requiring smaller sample size. Finally, the understanding of RIPerC mechanisms and its neuroprotective role will be a key and animal models studies surely encourage better refined and translation into humans for the treatment of ischemic stroke.

Conclusions {#Sec6}
===========

The summary of the completed and ongoing RCTs on RIPerC in IS patients shows that RIC can be initiated during pre-hospital transport, and it can be used alone or in combination with current recanalization therapies. RIPerC has the advantages of simplicity, safety, feasibility and affordability. The exact time window and the most effective neuroprotective RIC protocol are still not fully determined. Stroke preclinical animal models and RIC research are needed, both will also contribute to define the RIC molecular effects. Finally, ongoing RCTs will provide new information on the effect of RIPerC in IS patients, the optimal RIC protocol application and the underlying RIPerC mechanisms.
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